Evidence map›Paper›PMID 32866988›Full record

ArticleThe British journal of dermatology2021

Immune tolerance of allogeneic haematopoietic cell transplantation supports donor epidermal grafting of recessive dystrophic epidermolysis bullosa chronic wounds.

C L Ebens, J A McGrath, J A Riedl, A R Keith, G Lilja, S Rusch, D R Keene, S F Tufa, M J Riddle, R Shanley and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Investigational Treatments for Epidermolysis Bullosa.American journal of clinical dermatology · 2021
    Review
  13. Article
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

C L EbensDivision of Blood and Marrow Transplantation, Department of Pediatrics, Medical School, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0003-2430-911X
J A McGrathSt John's Institute of Dermatology, King's College London, London, England.ORCID 0000-0002-3708-9964
J A RiedlDepartment of Microbiology, Immunology, and Cancer Biology, University of Minnesota, Minneapolis, MN, USA.
A R KeithDepartment of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, MN, USA.
G LiljaDivision of Blood and Marrow Transplantation, Department of Pediatrics, Medical School, University of Minnesota, Minneapolis, MN, USA.
S RuschDivision of Blood and Marrow Transplantation, Department of Pediatrics, Medical School, University of Minnesota, Minneapolis, MN, USA.
D R KeeneMicroimaging Center, Shriners Hospital for Children, Portland, OR, USA.
S F TufaMicroimaging Center, Shriners Hospital for Children, Portland, OR, USA.
M J RiddleDivision of Blood and Marrow Transplantation, Department of Pediatrics, Medical School, University of Minnesota, Minneapolis, MN, USA.
R ShanleyBiostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
A E Van HeestDepartment of Orthopaedic Surgery, University of Minnesota, Minneapolis, MN, USA.
J TolarDivision of Blood and Marrow Transplantation, Department of Pediatrics, Medical School, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-0957-4380
University of Minnesota Medical Center · USUniversity of Minnesota · USShriners Hospitals for Children - Portland · USKing's College London · GB

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Institutional Career Development CoreKL2TR002492 · NCATS · UNIVERSITY OF MINNESOTA · PI INGBAR, DAVID H · 2018 to 2022
$6.3M
EB CharitiesNCATS NIH HHS KL2 TR002492NCATS NIH HHS UL1 TR002494NCI NIH HHS P30 CA077598Richard M. Schulze Family FoundationZona Family Foundation for EB Research
6 · The paper itself

Abstract

backgroundChronic wounds, a common morbidity in recessive dystrophic epidermolysis bullosa (RDEB), lack definitive therapies.

objectivesTo assess allogeneic epidermal skin grafts in terms of wound healing and durability over time.

methodsIn a prospective, open-label clinical trial for postallogeneic haematopoietic cell transplantation (post-alloHCT) patients with RDEB, up to nine chronic wounds per patient were grafted over 1 year. Epidermal grafts measuring 5 cm

resultsBetween August 2016 and January 2019, eight patients with RDEB received a total of 35 epidermal allografts at a median of 1157 days (range 548-2884) post-alloHCT. The median (interquartile range) percentage reductions in wound surface area were 75% (52-94), 95% (72-100) and 100% (97-100) at 6, 12 and 52 weeks postgraft, respectively, each significantly reduced from baseline (P < 0·001). Donor harvest sites healed quickly without scarring. Biopsy evaluation at 1 year of an epidermal allograft site revealed wildtype type VII collagen (immunofluorescence), anchoring fibrils (electron microscopy), and full-thickness skin whole-DNA donor chimerism of 42% (compared with 16% in concurrently biopsied native skin). This strategy subsequently supported release of RDEB pseudosyndactyly.

conclusionsThe immune tolerance established by alloHCT supports successful adoptive transfer of donor epidermal grafts. Persistence of donor grafts in a single patient beyond 1 year and observed migration of donor-grafted cells into adjacent wound suggest that epidermal allografts include nonterminally differentiated cells and/or trigger recruitment of donor bone-marrow-derived cells to mediate wound healing.

Indexed as

Epidermolysis Bullosa DystrophicaHematopoietic Stem Cell TransplantationCollagen Type VIIHumansImmune ToleranceProspective StudiesCollagen Type VII

Identifiers

PMID32866988
PMCPMC7914301
OpenAlexW3082879697

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.